.jpg)
.jpg)
urologic oncology
University of Miami Miller School of Medicine
Mark Soloway, MD Joined Memorial Hospital in 2014. He had served as Professor and Chair of the Department of Urology at the University of Miami from 1991 to 2010.
Dr. Soloway graduated from Case Western Reserve Medical School . He is a member of AOA. His residency was at University Hospitals of Cleveland. He was a clinical associate in the Surgery Branch of the NCI . His developed an animal model for bladder cancer (BC). He found that the investigational drug, cis diamminedichloroplatinum (cisplatin), was effective in reducing tumor growth . This lead to the successful use of cisplatin in patients with advanced BC. He later supervised the clincial use of cisplatin.
His animal and clinical work demonstrated the synergy of radiation and cisplatin which led to randomized trials confirming the synergy. This remains a principle for bladder preservation for locally advanced BC.
Dr. Soloway demonstrated that tumor implantation preferentially occurs on an altered urothelial surface which supports the concept of post TUR intravesical chemotherapy. He was the first to demonstrate the feasibility and safety of active surveillance for low grade Ta bladder tumors.
In the area of prostate cancer, Dr. Soloway published on bladder neck preservation, the implication of positive margins, and the failure of neoadjuvant androgen deprivation prior to RP. He popularized the periprostatic nerve block prior to transrectal ultrasound prostate biopsies
In 1984 Dr. Soloway received the Gold Cystoscope Award. given annually to the urologist who contributes most to the specialty within 10 years of completing their residency In 2014 he gave the Society of Urologic Oncology Whitmore Memorial Lecture. He was awarded the St. Paul Medal from the British Association of Urologic Surgeons in 2015. Dr. Soloway has authored more than 560 articles in peer reviewed journals and over 50 book chapters.
Disclosure information not submitted.
Monday, May 16, 2022
1:30 PM – 3:30 PM